Tobira Therapeutics Inc. Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection
1/7/2013 10:30:05 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics today announced positive results from the 24-week primary analysis of Study 202, the Phase 2b study of cenicriviroc (CVC). CVC is a novel, oral, once-daily, dual CCR5/CCR2 inhibitor. Tobira is investigating CVC for the treatment of HIV-1 infected adults with CCR5-tropic virus. This 143-patient, double-blind, double-dummy, randomized, controlled Phase 2b trial (Study 202, NCT01338883) met its primary objective over 24 weeks of treatment. A similar proportion of patients treated with either 100mg or 200mg of once-daily CVC plus Truvada® (emtricitabine/tenofovir disoproxil fumarate) achieved undetectable HIV viral load (<50c/mL) at week 24 when compared to patients treated with once-daily Sustiva® (efavirenz) plus Truvada®. A favorable safety and tolerability profile was observed in CVC-treated patients.